New Longevity Clinical Trial (STAY)

Longevity Tip: New Longevity Clinical Trial (STAY)

Tip Summary: A clinical trial, known as the STAY study, has launched, focusing on a novel drug, LOY-002, designed to extend the healthy lifespan of senior dogs.

Hey Dog Longevity friends! Every day in the dog longevity world seems to bring something new - we’re in exciting times! A new study was recently launched to help support our dogs’ longevity through novel mechanisms. The STAY study introduces LOY-002, a drug targeting the metabolic health of senior dogs to combat age-related diseases. Let’s take a closer look at the study's core aspects, and discuss the impact on longevity:

1. Drug Development: LOY-002 aims to improve senior dogs' metabolic health, potentially delaying or mitigating the impact of aging. This approach is distinct from LOY-001, which focuses on large breeds by reducing IGF-1 levels.

2. Clinical Trial: The STAY study plans to enroll 1,000 dogs across the U.S., making it one of the most extensive veterinary clinical trials to date.

3. Participatory Research: With over 50 veterinary clinics participating, the study emphasizes community involvement in advancing canine health research.

4. Data Collection: The trial includes a biobank of saliva and blood samples, aiming to support future product development and research into dog and human longevity.

Impact on Longevity: By focusing on metabolic health in senior dogs, LOY-002 could significantly extend not just the lifespan but the quality of life for aging canines. This trial's findings could pave the way for new standards in veterinary care, helping to grow awareness of longevity solutions that exist for our dogs, ultimately allowing us to get more time with our best friends.

Source: DVM360

P.S. - If you don’t want to wait years to help support your dog’s longevity, Longevity & Vitality daily chews are available today, which can help revitalize your dog’s cells and help them to live longer.